Illumina, Inc. 

(Public, NASDAQ:ILMN)   Watch this stock   
Find more results for ILMN
Dec 2, 2009
Piper Jaffray Healthcare Conference - 11:00AM EST - Add to calendar
Oct 27, 2009
Q3 2009 Earnings Conference Call - Webcast
Oct 27, 2009
Q3 2009 Earnings Release
Sep 22, 2009
UBS Global Life Sciences Conference
Sep 15, 2009
Morgan Stanley Global Healthcare Conference - Webcast
Sep 10, 2009
Thomas Weisel Partners Healthcare Conference
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin 10.78% 8.81%
Operating margin 18.50% 14.04%
EBITD margin - 18.87%
Return on average assets 4.54% 4.27%
Return on average equity 7.05% 8.01%
Employees 1,536 -

Address

9885 Towne Centre Drive
San Diego, CA 92121
United States - Map
+1-858-2024500 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Illumina, Inc. discussions

  View all discussions »

Description

Illumina, Inc. is a developer, manufacturer and marketer of integrated systems for the large-scale analysis of genetic variation and biological function. The Company provides a comprehensive line of products and services that serve the sequencing, genotyping and gene expression markets. It also, develops and commercializes sequencing technologies used to perform a range of analyses, including whole genome re-sequencing, gene expression analysis and small ribonucleic acid (RNA) analysis. Its customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations and biotechnology companies. The Company operates in two business segments: Life Sciences and Diagnostics. On August 1, 2008, the Company acquired Avantome, Inc. The Company’s subsidiary is Solexa, Inc.

Officers and directors

William H. Rastetter Ph.D.
Chairman of the Board
Age: 61
Bio & Compensation - Reuters
Jay T. Flatley
President, Chief Executive Officer, Director
Age: 56
Bio & Compensation - Reuters
Christian O. Henry
Chief Financial Officer, Senior Vice President - Corporate Development
Age: 40
Bio & Compensation - Reuters
David R. Walt Ph.D.
Chairman - Scientific Advisory Board, Director
Age: 56
Bio & Compensation - Reuters
Mostafa Ronaghi Ph.D.
Senior Vice President, Chief Technology Officer
Age: 40
Bio & Compensation - Reuters
Christian G. Cabou
Senior Vice President, General Counsel, Secretary
Age: 60
Bio & Compensation - Reuters
Joel McComb
Senior Vice President, General Manager - Life Sciences Business Unit
Age: 44
Bio & Compensation - Reuters
Gregory F. Heath Ph.D.
Senior Vice President, General Manager - Diagnostics Business Unit
Age: 51
Bio & Compensation - Reuters
Tristan B. Orpin
Senior Vice President - Commercial Operations
Age: 42
Bio & Compensation - Reuters
Daniel M. Bradbury
Director
Age: 48
Bio & Compensation - Reuters